Product Pipeline

Biotherapeutic Indication Funding Preclinical Phase 1 Phase 2 Phase 3 NDA

AEOL 10150

Radiation Oncology Company
Preclinical Phase completed
Phase 1 in progress
Phase 2 not started
Phase 3 not started
NDA not started

AEOL 10150

Idiopathic Pulmonary Fibrosis Company
Preclinical Phase completed
Phase 1 in progress
Phase 2 not started
Phase 3 not started
NDA not started

AEOL 11114

Parkinson's Disease M.J. Fox Foundation
Preclinical Phase in progress

AEOL 11114

Epilepsy CURE Foundation
Preclinical Phase in progress

AEOL 20415

Infectious Disease Company
Preclinical Phase in progress
BioDefense
(Animal Rule)
Indication Funding TRL1 TRL2 TRL3 TRL4 TRL5 TRL6 TRL7 TRL8 TRL9 NDA

AEOL 10150

Acute Radiation Syndrome - Lung BARDA
$118.4MM Contract.
TRL1 Phase completed
TRL2 Phase completed
TRL3 Phase completed
TRL4 Phase completed
TRL5 Phase completed
TRL6 Phase completed
TRL7 in progress
TRL8 not started
TRL9 not started
NDA not started

AEOL 10150

Chemical Gas Exposure NIH
TRL1 Phase completed
TRL2 Phase completed
TRL3 Phase completed
TRL4 Phase completed
TRL5 Phase completed
TRL6 Phase completed
TRL7 in progress
TRL8 not started
TRL9 not started
NDA not started

AEOL 10150

Nerve Gas Exposure NIH
TRL1 Phase completed
TRL2 Phase completed
TRL3 Phase completed

Phase Structure

Pre-Clinical
TRL 1
Basic Research
TRL 2
Basic Invention
TRL 3
Initial Validation of Analytical Components
TRL 4
Transition from Research to Development
TRL 5
Product Development/Begin Design Controls
TRL 6
Pre-Clinical/In-House Testing
Phase 1
TRL 7
Investigational Phase
Phase 2
TRL 8
End of System Development; Use in Actual Setting with Clinical Samples
Phase 3
TRL 9
Used in Clincial Settings w/ Clinical Samples, Post-Market Studies or Data Collection